ClinicalTrials.gg
TerminatedNCT04775316Updated Dec 2, 2022

Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing

An observational study in Wounds and Injuries and Skin Diseases, sponsored by BSN Medical GmbH. Terminated at 3 sites in Germany. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2022-12-02.

Sponsored by BSN Medical GmbH · Observational

How we know

Why this study was terminated
site stopped recruiting due to limited personell resources

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
47
Ages
65 Years and older
Sex
All
01

Study summary

Although, a huge number of acute wounds is treated successfully every year, Health Care Professionals (HCPs) are facing more and more problems when treating skin damages or surgical incisions: The number of patients with fragile and/or sensitive skin is highly increasing. Such patients are having a skin integrity issue, meaning the skin is vulnerable to injury, often damaged, or unable to heal.

The investigational medical devices (IMDs) of the planned clinical evaluation, Leukomed® T skin sensitive and Leukomed® T plus skin sensitive have been developed for treatment of acute wounds on patients with fragile or sensitive skin to provide a reliable but skin-friendly fixation and wound care option.

The primary purpose of this clinical study is the evaluation of clinical performance to stay in place up to seven days and the safety of both dressings. Further, data on wearing comfort, product handling, pain during removal and quality of life are considered as secondary outcomes. The products will be used as part of routine wound care within the scope of their intended purpose without any additional invasive or burdensome examination.

02

Conditions studied

  • Wounds and Injuries
  • Skin Diseases
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's enrollment of 47 is below the median of 169 across 690 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects 65 years and older suffering from skin changes causing fragile skin. Extrinsic factors and intrinsic factors leading to skin damages or pathological changes: extremes of ager (>80 years), race/ethnicity, underlaying medical conditions, dermatological conditions, malnutrition, dehydration, drying of the skin, prolonged exposure to moisture, certain medication, current radiotherapy, photedamage, previous removal of tapes/dressings/devices, repeated taping. Subject presenting on of the criteria above can be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men, women or diverse
  • ≥ 65 years of age
  • Patient is mentally and physically able to participate in this study
  • Signed to participate in this study
  • Fragile skin condition
  • Acute wound (surgical wound or laceration), indicated for treatment with the products for a time period of 7 days

Exclusion criteria

Exclusion Criteria:

  • Infection of the target wound
  • Alcohol or drug addiction
  • Known sensitivity or allergy to any component of the study product
  • Patients who participate in any other clinical study investigating drugs or medical devices
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
47 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with fragile skin

    Patient aged 65 years and older presenting with fragile skin and require wound care of an acute wound (laceration or surgical wound). Siliconized sterile wound dressing will be applied for a treatment period of 7 days.

    Device: Leukomed T / Tplus skin sensitive treatment

Interventions

  • DeviceLeukomed T / Tplus skin sensitive treatment

    Application of sterile wound dressing.

06

What researchers measure

Primary outcomes

  1. Adhered dressing area after wear

    Percentage of adhered dressing area 7 days after application

    Time frame: 7 days after dressing application

Secondary outcomes

  1. Skin damage

    skin damage after dressing removal

    Time frame: 7 days after dressing application

  2. Skin reddening

    Reddening of the skin 30 min after dressing removal

    Time frame: 7 days after dressing application

  3. Skin reactions

    Further skin reactions after dressing removal

    Time frame: after 7 days

  4. Pain assessment

    Pain at dressing removal

    Time frame: 7 days after dressing application

  5. Product Evaluation by patient

    Judge wearing comfort

    Time frame: 7 days after dressing application

  6. Product Evaluation by Health Care Professional

    Assessment of handling, application and and re-application

    Time frame: at application day (day 0)

  7. Infection

    Assess signs of wound infection

    Time frame: 7 days after dressing application

07

Study locations

3 sites
  • Practice Degenhardt
    Bremen, Germany
  • Klinikum Dortmund
    Dortmund, Germany
  • orthoGroup
    Hamburg, Germany
08

References and documents

Individual participant data

Plan to share: No — data will not be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Nov 2022, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 1, 2021
StartActual
Sep 1, 2021
Primary completionActual
Nov 28, 2022
CompletionActual
Nov 30, 2022
Last update
Dec 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04775316
Lead sponsor
BSN Medical GmbH
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Sep 1, 2021
Primary completion
Nov 28, 2022
Completion
Nov 30, 2022
Last update
Dec 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion